Ning-Shao Xia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7266571/publications.pdf

Version: 2024-02-01

447 papers 18,789 citations

18482 62 h-index 20961 115 g-index

485 all docs 485 docs citations

485 times ranked 22845 citing authors

#	Article	lF	CITATIONS
1	Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies. Journal of Infectious Diseases, 2023, 227, 488-497.	4.0	10
2	Nucleic Acid Testing for Coronavirus Disease 2019: Demand, Research Progression, and Perspective. Critical Reviews in Analytical Chemistry, 2022, 52, 413-424.	3. 5	25
3	The Risk of Transfusion-Transmitted Hepatitis E Virus: Evidence from Seroprevalence Screening of Blood Donations. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 145-152.	0.6	5
4	Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. Protein and Cell, 2022, 13, 72-77.	11.0	6
5	Machine Learning for Structure Determination in Single-Particle Cryo-Electron Microscopy: A Systematic Review. IEEE Transactions on Neural Networks and Learning Systems, 2022, 33, 452-472.	11.3	5
6	Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters. Cellular and Molecular Immunology, 2022, 19, 290-292.	10.5	17
7	5' preS1 mutations to prevent large envelope protein expression from hepatitis B virus genotype A or genotype D markedly increase polymerase-envelope fusion protein. Journal of Virology, 2022, , JVI0172321.	3.4	O
8	An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations. Biosensors and Bioelectronics, 2022, 203, 114032.	10.1	7
9	A stepwise docking molecular dynamics approach for simulating antibody recognition with substantial conformational changes. Computational and Structural Biotechnology Journal, 2022, 20, 710-720.	4.1	1
10	A hand-held, real-time, Al-assisted capillary convection PCR system for point-of-care diagnosis of African swine fever virus. Sensors and Actuators B: Chemical, 2022, 358, 131476.	7.8	6
11	Development of a skin- and neuro-attenuated live vaccine for varicella. Nature Communications, 2022, 13, 824.	12.8	10
12	A review of the safety and efficacy of current COVID-19 vaccines. Frontiers of Medicine, 2022, 16, 39-55.	3.4	19
13	Establishment of Sandwich ELISA for Quality Control in Rotavirus Vaccine Production. Vaccines, 2022, 10, 243.	4.4	2
14	Female sex hormone, progesterone, ameliorates the severity of SARS-CoV-2-caused pneumonia in the Syrian hamster model. Signal Transduction and Targeted Therapy, 2022, 7, 47.	17.1	12
15	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Frontiers in Microbiology, 2022, 13, 828806.	3.5	17
16	A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy. Antiviral Research, 2022, 199, 105265.	4.1	4
17	The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. Emerging Microbes and Infections, 2022, 11, 793-803.	6.5	14
18	A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge <i>In Vivo</i> Journal of Virology, 2022, 96, e0007522.	3.4	8

#	Article	IF	CITATIONS
19	Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209. Cell Research, 2022, 32, 491-494.	12.0	17
20	Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells. Virologica Sinica, 2022, , .	3.0	0
21	Pre-existing maternal IgG antibodies as a protective factor against congenital cytomegalovirus infection: A mother-child prospective cohort study. EBioMedicine, 2022, 77, 103885.	6.1	5
22	Molecular Evolution of Attachment Glycoprotein (G) and Fusion Protein (F) Genes of Respiratory Syncytial Virus ON1 and BA9 Strains in Xiamen, China. Microbiology Spectrum, 2022, 10, e0208321.	3.0	6
23	Risk of hepatocellular carcinoma in antiviral treatment-na \tilde{A} -ve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer, 2022, 22, 287.	2.6	17
24	Structures of pseudorabies virus capsids. Nature Communications, 2022, 13, 1533.	12.8	11
25	A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. Emerging Microbes and Infections, 2022, 11, 914-925.	6.5	8
26	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Cell Reports, 2022, 38, 110558.	6.4	15
27	Whole blood GBP5 protein levels in patients with and without active tuberculosis. BMC Infectious Diseases, 2022, 22, 328.	2.9	4
28	HER2/PD1 bispecific antibody in IgG4 subclass with superior antiâ€tumour activities. Clinical and Translational Medicine, 2022, 12, e791.	4.0	2
29	A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D. Antiviral Research, 2022, 201, 105298.	4.1	3
30	Development of a rapid neutralization assay for the detection of neutralizing antibodies against coxsackievirus B1. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115676.	1.8	1
31	A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nature Nanotechnology, 2022, 17, 531-540.	31.5	125
32	Long-Term immunopersistence and safety of the <i>Escherichia coli</i> -produced HPV-16/18 bivalent vaccine in Chinese adolescent girls. Human Vaccines and Immunotherapeutics, 2022, 18, 1-8.	3.3	1
33	Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. Cell Reports, 2022, 39, 110862.	6.4	9
34	A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice. Frontiers in Microbiology, 2022, 13, 854630.	3.5	3
35	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin, 2022, 67, 1372-1387.	9.0	54
36	Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respiratory Medicine, the, 2022, 10, 749-760.	10.7	65

3

#	Article	IF	Citations
37	PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	8
38	Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells. Frontiers in Immunology, 2022, 13, .	4.8	4
39	Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. Journal of Virological Methods, 2022, , 114564.	2.1	7
40	Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade., 2022, 10, e004762.		19
41	A Hemagglutinin Stem Vaccine Designed Rationally by AlphaFold2 Confers Broad Protection against Influenza B Infection. Viruses, 2022, 14, 1305.	3.3	3
42	Recent progress in antibody-based therapeutics for triple-negative breast cancer. Expert Opinion on Drug Delivery, 2022, 19, 815-832.	5.0	4
43	Safety and immunogenicity of an <i>Escherichia coli</i> -produced bivalent human papillomavirus type $6/11$ vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	2
44	New discovery of high-affinity SARS-CoV-2 spike S2 protein binding peptide selected by PhIP-Seq. Virologica Sinica, 2022, 37, 758-761.	3.0	0
45	An Integrated, Real-Time Convective PCR System for Isolation, Amplification, and Detection of Nucleic Acids. Chemosensors, 2022, 10, 271.	3.6	4
46	Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses. Virology, 2022, 574, 1-8.	2.4	1
47	Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in Close Contacts of Coronavirus Disease 2019 (COVID-19) Patients: A Seroepidemiological Study. Clinical Infectious Diseases, 2021, 73, 553-554.	5.8	18
48	SAMD4 family members suppress human hepatitis B virus by directly binding to the Smaug recognition region of viral RNA. Cellular and Molecular Immunology, 2021, 18, 1032-1044.	10.5	9
49	Establishment of a rapid ELISPOT assay for influenza virus titration and neutralizing antibody detection. Journal of Medical Virology, 2021, 93, 3455-3464.	5.0	8
50	Naturally occurring $5\hat{a} \in \mathbb{Z}^2$ preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C. Gut, 2021, 70, 575-584.	12.1	12
51	Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. National Science Review, 2021, 8, nwaa291.	9.5	72
52	Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. Emerging Microbes and Infections, 2021, 10, 37-50.	6.5	11
53	Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. Emerging Microbes and Infections, 2021, 10, 365-375.	6.5	33
54	A SCID mouse-human lung xenograft model of SARS-CoV-2 infection. Theranostics, 2021, 11, 6607-6615.	10.0	8

#	Article	IF	CITATIONS
55	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. Emerging Microbes and Infections, 2021, 10, 1881-1889.	6.5	10
56	Adefovir dipivoxil efficiently inhibits the proliferation of pseudorabies virus in vitro and in vivo. Antiviral Research, 2021, 186, 105014.	4.1	8
57	Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host and Microbe, 2021, 29, 448-462.e5.	11.0	19
58	Structural Basis for the Shared Neutralization Mechanism of Three Classes of Human Papillomavirus Type 58 Antibodies with Disparate Modes of Binding. Journal of Virology, 2021, 95, .	3.4	4
59	Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundamental Research, 2021, 1, 139-150.	3.3	19
60	The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nature Communications, 2021, 12, 1383.	12.8	37
61	Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Signal Transduction and Targeted Therapy, 2021, 6, 136.	17.1	57
62	Role of Small Envelope Protein in Sustaining the Intracellular and Extracellular Levels of Hepatitis B Virus Large and Middle Envelope Proteins. Viruses, 2021, 13, 613.	3.3	4
63	Sporadic hand, foot, and mouth disease cases associated with non-C4 enterovirus 71 strains in Xiamen, China, from 2009 to 2018. Archives of Virology, 2021, 166, 2263-2266.	2.1	1
64	A Novel Clustering Method Using Variational Autoencoder with Reliable Sample Decision and Balanced K-Means++ for Single-particle Cryo-EM Images. , 2021, , .		0
65	Elimination of human cytomegalovirus DNA degradation in urine. Journal of Medical Virology, 2021, 93, 5033-5039.	5.0	6
66	Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy. Journal of Hepatology, 2021, 74, 1315-1324.	3.7	29
67	Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China. Indian Journal of Gynecologic Oncology, 2021, 19, 51.	0.3	7
68	Lost Small Envelope Protein Expression from Naturally Occurring PreS1 Deletion Mutants of Hepatitis B Virus Is Often Accompanied by Increased HBx and Core Protein Expression as Well as Genome Replication. Journal of Virology, 2021, 95, e0066021.	3.4	4
69	Carbohydrate-containing nanoparticles as vaccine adjuvants. Expert Review of Vaccines, 2021, 20, 797-810.	4.4	7
70	Comparison of detection strategies for screening and confirming congenital cytomegalovirus infection in newborns in a highly seroprevalent population: a mother-child cohort study. The Lancet Regional Health - Western Pacific, 2021, 12, 100182.	2.9	13
71	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Science Translational Medicine, 2021, 13, .	12.4	56
72	Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein. Vaccines, 2021, 9, 829.	4.4	9

#	Article	IF	CITATIONS
73	Accurate nucleic acid quantification in a single sample tube without the need for calibration. Analytica Chimica Acta, 2021, 1167, 338599.	5.4	1
74	Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo. Nature Communications, 2021, 12, 5131.	12.8	44
75	Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study. The Lancet Regional Health - Western Pacific, 2021, 13, 100196.	2.9	5
76	Development of A Neonatal Mouse Model for Coxsackievirus B1 Antiviral Evaluation. Virologica Sinica, 2021, 36, 1575-1584.	3.0	7
77	Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice. Antibody Therapeutics, 2021, 4, 197-207.	1.9	1
78	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV,the, 2021, 8, e531-e543.	4.7	77
79	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nature Communications, 2021, 12, 5652.	12.8	49
80	Rapid PCR powered by microfluidics: A quick review under the background of COVID-19 pandemic. TrAC - Trends in Analytical Chemistry, 2021, 143, 116377.	11.4	65
81	Transferable, easy-to-use and room-temperature-storable PCR mixes for microfluidic molecular diagnostics. Talanta, 2021, 235, 122797.	5.5	4
82	Virusâ€Free and Liveâ€Cell Visualizing SARSâ€CoVâ€2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods, 2021, 5, 2001031.	8.6	25
83	Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region. Viruses, 2021, 13, 2380.	3.3	8
84	Engineering for an HPV 9-valent vaccine candidate using genomic constitutive over-expression and low lipopolysaccharide levels in Escherichia coli cells. Microbial Cell Factories, 2021, 20, 227.	4.0	5
85	Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. Journal of the National Cancer Institute, 2020, 112, 145-153.	6.3	99
86	Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Science China Life Sciences, 2020, 63, 582-591.	4.9	34
87	A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut, 2020, 69, 343-354.	12.1	34
88	Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study. Clinical Infectious Diseases, 2020, 70, 82-89.	5.8	15
89	Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods. Journal of Pharmaceutical and Biomedical Analysis, 2020, 177, 112880.	2.8	10
90	Rapid Neutralization Testing System for Zika Virus Based on an Enzyme-Linked Immunospot Assay. ACS Infectious Diseases, 2020, 6, 811-819.	3.8	8

#	Article	IF	Citations
91	Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18–45 years enrolled in a clinical trial. Clinical Microbiology and Infection, 2020, 26, 1069-1075.	6.0	6
92	Capsid destabilization and epitope alterations of human papillomavirus 18 in the presence of thimerosal. Journal of Pharmaceutical Analysis, 2020, 11, 617-627.	5.3	4
93	A novel point-of-care test of respiratory syncytial viral RNA based on cellulose-based purification and convective PCR. Clinica Chimica Acta, 2020, 511, 154-159.	1.1	3
94	Free convective PCR: From principle study to commercial applicationsâ€"A critical review. Analytica Chimica Acta, 2020, 1108, 177-197.	5.4	27
95	Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nature Communications, 2020, 11, 3971.	12.8	19
96	Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. , 2020, 8, e000515.		27
97	Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. Vaccine, 2020, 38, 6096-6102.	3.8	9
98	A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research, 2020, 30, 936-939.	12.0	116
99	Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes. Journal of Virology, 2020, 94, .	3.4	7
100	Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China. Emerging Infectious Diseases, 2020, 26, 2387-2393.	4.3	10
101	Near-atomic cryo-electron microscopy structures of varicella-zoster virus capsids. Nature Microbiology, 2020, 5, 1542-1552.	13.3	7
102	Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerging Microbes and Infections, 2020, 9, 2105-2113.	6.5	124
103	Expression Level of Small Envelope Protein in Addition to Sequence Divergence inside Its Major Hydrophilic Region Contributes to More Efficient Surface Antigen Secretion by Hepatitis B Virus Subgenotype D2 than Subgenotype A2. Viruses, 2020, 12, 967.	3.3	2
104	SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Emerging Microbes and Infections, 2020, 9, 2076-2090.	6.5	53
105	Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks. International Journal of Molecular Sciences, 2020, 21, 6461.	4.1	109
106	Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. European Respiratory Journal, 2020, 56, 2000763.	6.7	374
107	Animal models for emerging coronavirus: progress and new insights. Emerging Microbes and Infections, 2020, 9, 949-961.	6.5	50
108	Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nature Communications, 2020, 11, 2841.	12.8	16

#	Article	IF	CITATIONS
109	Genome re-sequencing and reannotation of the Escherichia coli ER2566 strain and transcriptome sequencing under overexpression conditions. BMC Genomics, 2020, 21, 407.	2.8	7
110	Molecular characterization of an uncommon multigene Reassortant G1P[4] rotavirus identified in China. Infection, Genetics and Evolution, 2020, 85, 104413.	2.3	2
111	Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development. Antiviral Research, 2020, 180, 104757.	4.1	6
112	Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2027-2034.	5.8	2,214
113	Intratumoral Delivery of a PD-1–Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Cancer Immunology Research, 2020, 8, 632-647.	3.4	42
114	Room-temperature-storable PCR mixes for SARS-CoV-2 detection. Clinical Biochemistry, 2020, 84, 73-78.	1.9	19
115	DLL4 restores damaged liver by enhancing hBMSC differentiation into cholangiocytes. Stem Cell Research, 2020, 47, 101900.	0.7	8
116	COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics, 2020, 10, 7821-7835.	10.0	121
117	Mitogen- and Stress-Activated Protein Kinase 1 Mediates Alcohol-Upregulated Transcription of Brf1 and tRNA Genes to Cause Phenotypic Alteration. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	4.0	7
118	Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. Oncolmmunology, 2020, 9, 1726168.	4.6	9
119	Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation. Viruses, 2020, 12, 109.	3. 3	16
120	Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent. Human Vaccines and Immunotherapeutics, 2020, 16, 1554-1564.	3.3	7
121	Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. Cell Host and Microbe, 2020, 27, 249-261.e5.	11.0	24
122	High-Efficiency Plasma Separator Based on Immunocapture and Filtration. Micromachines, 2020, 11, 352.	2.9	10
123	Recent Progress on the Versatility of Virus-Like Particles. Vaccines, 2020, 8, 139.	4.4	110
124	Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro. Frontiers in Pharmacology, 2020, 11, 609592.	3.5	22
125	Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. Antibody Therapeutics, 2020, 3, 285-299.	1.9	34
126	Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. Clinical Gastroenterology and Hepatology, 2019, 17, 172-181.e1.	4.4	20

#	Article	IF	Citations
127	The Optimal Concentration of Formaldehyde is Key to Stabilizing the Pre-Fusion Conformation of Respiratory Syncytial Virus Fusion Protein. Viruses, 2019, 11, 628.	3.3	4
128	Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. Nature Communications, 2019, 10, 3192.	12.8	28
129	HIV-1 Membrane-Proximal External Region Fused to Diphtheria Toxin Domain-A Elicits 4E10-Like Antibodies in Mice. Immunology Letters, 2019, 213, 30-38.	2.5	3
130	Liver chimeric mice with tupaia hepatocyte transplantation as an animal model for hepatitis B virus infection and antiviral therapy. Biosafety and Health, 2019, 1, 76-83.	2.7	0
131	Nanobody-based sandwich reporter system for living cell sensing influenza A virus infection. Scientific Reports, 2019, 9, 15899.	3.3	12
132	Simultaneous <i>in situ</i> visualization and quantitation of dual antigens adsorbed on adjuvants using high content analysis. Nanomedicine, 2019, 14, 2535-2548.	3.3	5
133	Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Annals of Oncology, 2019, 30, 1630-1637.	1.2	85
134	Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma. Molecular Therapy - Oncolytics, 2019, 15, 153-165.	4.4	19
135	Structure and function analysis of the C. elegans aminophospholipid translocase TAT–1. Journal of Cell Science, 2019, 132, .	2.0	3
136	HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation. Gut, 2019, 68, 2044-2056.	12.1	46
137	Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infectious Diseases, The, 2019, 19, 880-891.	9.1	85
138	Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development. Cancer Immunology Research, 2019, 7, 1244-1257.	3.4	51
139	Molecular epidemiology of group A rotavirus in outpatient diarrhea infants and children in Chongqing, China, 2011â€2015. Journal of Medical Virology, 2019, 91, 1788-1796.	5.0	9
140	An efficient isothermal PCR method for on-site detection of nucleic acid. BioTechniques, 2019, 67, 63-69.	1.8	3
141	Robust <i>in vitro</i> assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerging Microbes and Infections, 2019, 8, 724-733.	6.5	3
142	Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 221-231.	4.3	12
143	The distinct impact of maternal antibodies on the immunogenicity of live and recombinant rotavirus vaccines. Vaccine, 2019, 37, 4061-4067.	3.8	7
144	Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAgâ€Positive Children With a Normal Alanine Aminotransferase Level. Hepatology, 2019, 70, 1903-1912.	7.3	11

#	Article	IF	CITATIONS
145	A point of care platform based on microfluidic chip for nucleic acid extraction in less than 1 minute. Biomicrofluidics, 2019, 13, 034102.	2.4	14
146	Prevalence, Concordance, and Transmission of Human Papillomavirus Infection Among Heterosexual Couples in Liuzhou, China: An Observational Perspective Study. Journal of Infectious Diseases, 2019, 220, 980-989.	4.0	10
147	Transcriptional response of USP18 predicts treatment outcomes of interferonâ€alpha in HBeAgâ€positive chronic hepatitis B patientsefere. Journal of Viral Hepatitis, 2019, 26, 1050-1058.	2.0	2
148	Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics, 2019, 9, 2115-2128.	10.0	11
149	Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels. Oral Oncology, 2019, 93, 85-90.	1.5	14
150	Construction of a bacterial surface display system based on outer membrane protein F. Microbial Cell Factories, 2019, 18, 70.	4.0	16
151	Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy. Advanced Materials, 2019, 31, e1808294.	21.0	63
152	Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study. International Journal of Cancer, 2019, 145, 807-816.	5.1	14
153	Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A. Antiviral Research, 2019, 164, 154-161.	4.1	8
154	An Optimized High-Throughput Neutralization Assay for Hepatitis E Virus (HEV) Involving Detection of Secreted Porf2. Viruses, 2019, 11, 64.	3.3	6
155	Characterization of native-like HIV-1 gp140 glycoprotein expressed in insect cells. Vaccine, 2019, 37, 1418-1427.	3.8	5
156	Real-time capillary convective PCR based on horizontal thermal convection. Microfluidics and Nanofluidics, 2019, 23, 1.	2.2	19
157	Viral neutralization by antibody-imposed physical disruption. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26933-26940.	7.1	9
158	Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection. Emerging Microbes and Infections, 2019, 8, 1721-1733.	6.5	11
159	Bibliometric analysis of oncolytic virus research, 2000 to 2018. Medicine (United States), 2019, 98, e16817.	1.0	31
160	Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. MBio, 2019, 10 , .	4.1	51
161	A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antiviral Research, 2019, 161, 28-35.	4.1	12
162	An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics, 2019, 9, 210-231.	10.0	37

#	Article	IF	CITATIONS
163	Development of an efficient neutralization assay for Coxsackievirus A10. Applied Microbiology and Biotechnology, 2019, 103, 1931-1938.	3.6	6
164	Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 1413-1415.	4.4	8
165	Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nature Microbiology, 2019, 4, 124-133.	13.3	40
166	An HRPâ€labeled lateral flow immunoassay for rapid simultaneous detection and differentiation of influenza A and B viruses. Journal of Medical Virology, 2019, 91, 503-507.	5.0	14
167	Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies. Journal of General Virology, 2019, 100, 237-245.	2.9	10
168	Application of Hepatitis E Virus-Related Markers on Samples from a Developing Country. Clinical Laboratory, 2019, 65, .	0.5	0
169	Development and evaluation of a rapid point-of-care test for detecting the hepatitis E virus antigen. Clinical Biochemistry, 2018, 55, 89-92.	1.9	4
170	Expression, Purification and Characterization of Hiv-1 Capsid Precursor Protein p41. Protein Journal, 2018, 37, 194-202.	1.6	0
171	Establishment and validation of a twoâ€step screening scheme for improved performance of serological screening of nasopharyngeal carcinoma. Cancer Medicine, 2018, 7, 1458-1467.	2.8	14
172	A Rapid On-Site Assay for the Detection of Influenza A by Capillary Convective PCR. Molecular Diagnosis and Therapy, 2018, 22, 225-234.	3.8	8
173	Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4773-4778.	7.1	125
174	Characterization and epitope mapping of a panel of monoclonal antibodies against HIVâ€1 matrix protein. Biotechnology and Applied Biochemistry, 2018, 65, 807-815.	3.1	0
175	Rapid detection of MERS coronavirus-like viruses in bats: potential for tracking MERS coronavirus transmission and animal origin. Emerging Microbes and Infections, 2018, 7, 1-7.	6.5	24
176	A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients. Digestive and Liver Disease, 2018, 50, 482-489.	0.9	15
177	Rapid enumeration of CD4 + T lymphocytes using an integrated microfluidic system based on Chemiluminescence image detection at point-of-care testing. Biomedical Microdevices, 2018, 20, 15.	2.8	10
178	Efficient development of a stable cell pool for antibody production using a single plasmid. Journal of Biochemistry, 2018, 163, 391-398.	1.7	1
179	Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerging Microbes and Infections, 2018, 7, 1-15.	6.5	33
180	Cytomegalovirus Shedding in Healthy Seropositive Female College Students: A 6-Month Longitudinal Study. Journal of Infectious Diseases, 2018, 217, 1069-1073.	4.0	19

#	Article	IF	Citations
181	An emerging and expanding clade accounts for the persistent outbreak of Coxsackievirus A6-associated hand, foot, and mouth disease in China since 2013. Virology, 2018, 518, 328-334.	2.4	16
182	Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine. Vaccine, 2018, 36, 2086-2092.	3.8	23
183	A low cost, membranes based serum separator modular. Biomicrofluidics, 2018, 12, 024108.	2.4	7
184	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. Journal of Hepatology, 2018, 69, 286-292.	3.7	76
185	Characterization of capsid protein (p495) of hepatitis E virus expressed in Escherichia coli and assembling into particles in vitro. Vaccine, 2018, 36, 2104-2111.	3.8	11
186	The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice. Human Vaccines and Immunotherapeutics, 2018, 14, 1779-1781.	3.3	3
187	Identification of Strategic Residues at the Interface of Antigen–Antibody Interactions by In Silico Mutagenesis. Interdisciplinary Sciences, Computational Life Sciences, 2018, 10, 438-448.	3.6	6
188	Rapid identification of imported influenza viruses at Xiamen International Airport via an active surveillance program. Clinical Microbiology and Infection, 2018, 24, 289-294.	6.0	9
189	A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys. Protein and Cell, 2018, 9, 130-134.	11.0	12
190	Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein and Cell, 2018, 9, 74-85.	11.0	57
191	Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or nearâ€normal alanine aminotransferase levels. Hepatology Research, 2018, 48, E133-E145.	3.4	32
192	The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: A populationâ€based study. International Journal of Cancer, 2018, 142, 1244-1251.	5.1	14
193	A bead-based microfluidic system for joint detection in TORCH screening at point-of-care testing. Microsystem Technologies, 2018, 24, 2007-2015.	2.0	5
194	A Single-Bead-Based, Fully Integrated Microfluidic System for High-Throughput CD4+T Lymphocyte Enumeration. SLAS Technology, 2018, 23, 134-143.	1.9	6
195	IL-6 release of Rv0183 antigen-stimulated whole blood is a potential biomarker for active tuberculosis patients. Journal of Infection, 2018, 76, 376-382.	3.3	4
196	Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant. Emerging Infectious Diseases, 2018, 24, 2241-2250.	4.3	167
197	Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine. Vaccine, 2018, 36, 7650-7658.	3.8	7
198	Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nature Communications, 2018, 9, 5360.	12.8	25

#	Article	IF	Citations
199	T = 4 Icosahedral HIV-1 Capsid As an Immunogenic Vector for HIV-1 V3 Loop Epitope Display. Viruses, 2018, 10, 667.	3.3	9
200	Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science Advances, 2018, 4, eaat7459.	10.3	19
201	N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in <i>Escherichia coli</i> and self-assembly in vitro. Emerging Microbes and Infections, 2018, 7, 1-12.	6.5	17
202	Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. Vaccine, 2018, 36, 6761-6771.	3.8	10
203	An automated microfluidic chemiluminescence immunoassay platform for quantitative detection of biomarkers. Biomedical Microdevices, 2018, 20, 91.	2.8	16
204	LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature, 2018, 562, 605-609.	27.8	172
205	Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors. Emerging Microbes and Infections, 2018, 7, 1-8.	6.5	21
206	An optimized high-throughput fluorescence plate reader-based RSV neutralization assay. Journal of Virological Methods, 2018, 260, 34-40.	2.1	2
207	A Chimeric Humanized Mouse Model by Engrafting the Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cell for the Chronic Hepatitis B Virus Infection. Frontiers in Microbiology, 2018, 9, 908.	3.5	28
208	Development of multiplex realâ€time reverseâ€transcriptase polymerase chain reaction assay for simultaneous detection of Zika, dengue, yellow fever, and chikungunya viruses in a single tube. Journal of Medical Virology, 2018, 90, 1681-1686.	5.0	29
209	ER stress regulating protein phosphatase 2A-B56γ, targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes. Cell Death and Disease, 2018, 9, 762.	6.3	29
210	Using MOEA with Redistribution and Consensus Branches to Infer Phylogenies. International Journal of Molecular Sciences, 2018, 19, 62.	4.1	5
211	Zika Virus Fatally Infects Wild Type Neonatal Mice and Replicates in Central Nervous System. Viruses, 2018, 10, 49.	3.3	39
212	Efficient mAb production in CHO cells with optimized signal peptide, codon, and UTR. Applied Microbiology and Biotechnology, 2018, 102, 5953-5964.	3.6	24
213	Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection. Emerging Microbes and Infections, 2018, 7, 1-17.	6.5	12
214	A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway. Theranostics, 2018, 8, 549-562.	10.0	51
215	Bioinspired Artificial Nanodecoys for Hepatitisâ€B Virus. Angewandte Chemie - International Edition, 2018, 57, 12499-12503.	13.8	46
216	Bioinspired Artificial Nanodecoys for Hepatitisâ€B Virus. Angewandte Chemie, 2018, 130, 12679-12683.	2.0	9

#	Article	IF	Citations
217	Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies. Journal of Infectious Diseases, 2018, 218, 1611-1621.	4.0	8
218	Structural Basis for the Broad, Antibody-Mediated Neutralization of H5N1 Influenza Virus. Journal of Virology, $2018, 92, .$	3.4	8
219	Hepatitis E Vaccines. , 2018, , 386-392.e4.		0
220	A Low-Cost and Fast Real-Time PCR System Based on Capillary Convection. SLAS Technology, 2017, 22, 13-17.	1.9	17
221	A smartphone-based point-of-care diagnosis of H1N1 with microfluidic convection PCR. Microsystem Technologies, 2017, 23, 2951-2956.	2.0	43
222	A novel toolbox for the in vitro assay of hepatitis D virus infection. Scientific Reports, 2017, 7, 40199.	3.3	3
223	The prevalence of latent tuberculosis infection in rural Jiangsu, China. Public Health, 2017, 146, 39-45.	2.9	15
224	Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in Escherichia coli. Protein Expression and Purification, 2017, 133, 110-120.	1.3	7
225	A paper-based microfluidic Dot-ELISA system with smartphone for the detection of influenza A. Microfluidics and Nanofluidics, 2017, 21, 1.	2.2	41
226	A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. Vaccine, 2017, 35, 2728-2735.	3.8	18
227	Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity. Vaccine, 2017, 35, 3222-3231.	3.8	7
228	A Smartphone-Based Genotyping Method for Hepatitis B Virus at Point-of-Care Settings. SLAS Technology, 2017, 22, 122-129.	1.9	12
229	Severe hand, foot and mouth disease associated with Coxsackievirus A10 infections in Xiamen, China in 2015. Journal of Clinical Virology, 2017, 93, 20-24.	3.1	59
230	Antibody-mediated immunotherapy against chronic hepatitis B virus infection. Human Vaccines and Immunotherapeutics, 2017, 13, 1768-1773.	3.3	32
231	A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Research, 2017, 144, 247-255.	4.1	25
232	Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater <i>In Vivo</i> Protection than the Murine Precursor of Palivizumab. Journal of Virology, 2017, 91, .	3.4	24
233	Epidemics and aetiology of hand, foot and mouth disease in Xiamen, China, from 2008 to 2015. Epidemiology and Infection, 2017, 145, 1865-1874.	2.1	30
234	Characterization and analysis of real-time capillary convective PCR toward commercialization. Biomicrofluidics, 2017, 11, 024103.	2.4	15

#	Article	IF	CITATIONS
235	Escherichia coli-derived virus-like particles in vaccine development. Npj Vaccines, 2017, 2, 3.	6.0	88
236	Instrument-free point-of-care molecular diagnosis of H1N1 based on microfluidic convective PCR. Sensors and Actuators B: Chemical, 2017, 243, 738-744.	7.8	47
237	Outer nuclear membrane fusion of adjacent nuclei in varicella-zoster virus-induced syncytia. Virology, 2017, 512, 34-38.	2.4	6
238	Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. MBio, 2017, 8, .	4.1	20
239	A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translational Medicine, 2017, 9, .	12.4	65
240	Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection. Applied Microbiology and Biotechnology, 2017, 101, 8585-8594.	3.6	3
241	A SCID mouse-human lung xenograft model of varicella-zoster virus infection. Antiviral Research, 2017, 146, 45-53.	4.1	6
242	Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nature Communications, 2017, 8, 505.	12.8	61
243	Characterization of an Escherichia coli -derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine, 2017, 35, 4637-4645.	3.8	32
244	Calcium phosphate nanoparticles as a new generation vaccine adjuvant. Expert Review of Vaccines, 2017, 16, 895-906.	4.4	59
245	Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications, 2017, 8, 1877.	12.8	53
246	Exploring a common mechanism of alcohol-induced deregulation of RNA Pol III genes in liver and breast cells. Gene, 2017, 626, 309-318.	2.2	12
247	Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. Scientific Reports, 2017, 7, 2747.	3.3	44
248	Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. Human Vaccines and Immunotherapeutics, 2017, 13, 2280-2291.	3.3	19
249	Varicella-zoster virus ORF7 interacts with ORF53 and plays a role in its trans-Golgi network localization. Virologica Sinica, 2017, 32, 387-395.	3.0	9
250	Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Frontiers of Medicine, 2017, 11, 502-508.	3.4	26
251	The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication. Theranostics, 2017, 7, 3090-3105.	10.0	39
252	Detection of HBV Covalently Closed Circular DNA. Viruses, 2017, 9, 139.	3.3	40

#	Article	IF	CITATIONS
253	Changing Epidemiology of Hepatitis A and Hepatitis E Viruses in China, 1990–2014. Emerging Infectious Diseases, 2017, 23, 276-279.	4.3	30
254	Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system. Emerging Microbes and Infections, 2017, 6, 1-8.	6.5	8
255	Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection. Oncotarget, 2017, 8, 73654-73669.	1.8	28
256	Using a Machine-Learning Approach to Predict Discontinuous Antibody-Specific B-Cell Epitopes. Current Bioinformatics, 2017, 12, .	1.5	5
257	Changing Epidemiology of Hepatitis A and Hepatitis E Viruses in China, 1990–2014. Emerging Infectious Diseases, 2017, 23, 276-279.	4.3	27
258	Anti-CD4: An Alternative Way to Inhibit HIV Infection. Journal of HIV & Retro Virus, 2016, 02, .	0.0	1
259	Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. International Journal of Molecular Sciences, 2016, 17, 1901.	4.1	14
260	Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Reviews in Medical Virology, 2016, 26, 115-128.	8.3	11
261	Detection of subtle differences in analogous viral capsid proteins by allowing unrestricted specific interaction in solution competition ELISA. Journal of Virological Methods, 2016, 236, 1-4.	2.1	7
262	An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice. Experimental Animals, 2016, 65, 373-382.	1.1	4
263	A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Scientific Reports, 2016, 6, 19042.	3.3	16
264	A fast and low-cost genotyping method for hepatitis B virus based on pattern recognition in point-of-care settings. Scientific Reports, 2016, 6, 28274.	3.3	11
265	The Bama miniature swine is susceptible to experimental HEV infection. Scientific Reports, 2016, 6, 31813.	3.3	10
266	A high-throughput neutralizing assay for antibodies and sera against hepatitis E virus. Scientific Reports, 2016, 6, 25141.	3.3	15
267	The ORF3 Protein of Genotype 1 Hepatitis E Virus Suppresses TLR3-induced NF-κB Signaling via TRADD and RIP1. Scientific Reports, 2016, 6, 27597.	3.3	48
268	Modulation of host CD59 expression by varicella-zoster virus in human xenografts in vivo. Virology, 2016, 491, 96-105.	2.4	8
269	A highly specific rapid antigen detection assay for on-site diagnosis of MERS. Journal of Infection, 2016, 73, 82-84.	3.3	39
270	Production of Influenza Virus HA1 Harboring Native-Like Epitopes by Pichia pastoris. Applied Biochemistry and Biotechnology, 2016, 179, 1275-1289.	2.9	4

#	Article	IF	Citations
271	Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines. Journal of Virological Methods, 2016, 234, 96-100.	2.1	13
272	A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6. Antiviral Research, 2016, 134, 50-57.	4.1	26
273	Prophylactic Hepatitis E Vaccine. Advances in Experimental Medicine and Biology, 2016, 948, 223-246.	1.6	10
274	A shared N-terminal hydrophobic tail for the formation of nanoparticulates. Nanomedicine, 2016, 11 , $2289-2303$.	3.3	5
275	Detection and analysis of tupaia hepatocytes via mAbs against tupaia serum albumin. Experimental Animals, 2016, 65, 117-123.	1.1	2
276	Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study. Emerging Microbes and Infections, 2016, 5, 1-8.	6.5	31
277	Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay. Applied Microbiology and Biotechnology, 2016, 100, 9321-9329.	3.6	6
278	Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants. Vaccine, 2016, 34, 4422-4428.	3.8	12
279	Immunogenicity and protective efficacy of rotavirus VP8 * fused to cholera toxin B subunit in a mouse model. Human Vaccines and Immunotherapeutics, 2016, 12, 2959-2968.	3.3	21
280	Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Science Translational Medicine, 2016, 8, 352ra108.	12.4	271
281	A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice. Vaccine, 2016, 34, 5938-5945.	3.8	12
282	Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. Scientific Reports, 2016, 6, 34531.	3.3	73
283	Serological Evaluation of Immunity to the Varicella-Zoster Virus Based on a Novel Competitive Enzyme-Linked Immunosorbent Assay. Scientific Reports, 2016, 6, 20577.	3.3	9
284	Real-time stability of a hepatitis E vaccine (Hecolin \hat{A}^{0}) demonstrated with potency assays and multifaceted physicochemical methods. Vaccine, 2016, 34, 5871-5877.	3.8	26
285	The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure. Science China Life Sciences, 2016, 59, 1198-1201.	4.9	1
286	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology, 2016, 65, 700-710.	3.7	331
287	Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera. Virology Journal, 2016, 13, 44.	3.4	12
288	The C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host Interaction. Structure, 2016, 24, 874-885.	3.3	24

#	Article	IF	Citations
289	Functional analysis of human cytomegalovirus UL/b′ region using SCID-hu mouse model. Journal of Medical Virology, 2016, 88, 1417-1426.	5.0	7
290	Prophylaxis against hepatitis E: at risk populations and human vaccines. Expert Review of Vaccines, 2016, 15, 815-827.	4.4	8
291	Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles. Applied Microbiology and Biotechnology, 2016, 100, 2809-2815.	3.6	8
292	A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice. Vaccine, 2016, 34, 1589-1596.	3.8	13
293	Development and evaluation of rapid point-of-care tests for detection of Enterovirus 71 and Coxsackievirus A16 specific immunoglublin M antibodies. Journal of Virological Methods, 2016, 231, 44-47.	2.1	14
294	Evaluation of a novel chemiluminescent microplate enzyme immunoassay for hepatitis B surface antigen detection. Journal of Virological Methods, 2016, 228, 55-59.	2.1	8
295	Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2016, 65, 658-671.	12.1	104
296	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut, 2016, 65, 313-320.	12.1	112
297	Functional characterization of hepatitis B virus core promoter mutants revealed transcriptional interference among co-terminal viral mRNAs. Journal of General Virology, 2016, 97, 2668-2676.	2.9	8
298	A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71. Scientific Reports, 2015, 5, 12973.	3.3	35
299	Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon. Theranostics, 2015, 5, 218-226.	10.0	54
300	Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody. PLoS ONE, 2015, 10, e0123944.	2.5	29
301	Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. PLoS ONE, 2015, 10, e0130209.	2.5	45
302	Long-Term Efficacy of a Hepatitis E Vaccine. New England Journal of Medicine, 2015, 372, 2265-2266.	27.0	29
303	The development of a recombinant hepatitis E vaccine HEV 239. Human Vaccines and Immunotherapeutics, 2015, 11, 908-914.	3.3	99
304	Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Human Vaccines and Immunotherapeutics, 2015, 11, 1277-1292.	3.3	39
305	A novel linear neutralizing epitope of hepatitis E virus. Vaccine, 2015, 33, 3504-3511.	3.8	25
306	Developing a genetically encoded green fluorescent protein mutant for sensitive light-up fluorescent sensing and cellular imaging of Hg(II). Analytica Chimica Acta, 2015, 876, 77-82.	5.4	19

#	Article	IF	CITATIONS
307	A phylogenetically distinct Middle East respiratory syndrome coronavirus detected in a dromedary calf from a closed dairy herd in Dubai with rising seroprevalence with age. Emerging Microbes and Infections, 2015, 4, 1-5.	6.5	24
308	A Valuable Antigen Detection Method for Diagnosis of Acute Hepatitis E. Journal of Clinical Microbiology, 2015, 53, 782-788.	3.9	54
309	A lysine-rich motif in the phosphatidylserine receptor PSR-1 mediates recognition and removal of apoptotic cells. Nature Communications, 2015, 6, 5717.	12.8	33
310	Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay. Journal of Virological Methods, 2015, 215-216, 56-60.	2.1	11
311	Long-Term Efficacy of a Hepatitis E Vaccine. New England Journal of Medicine, 2015, 372, 914-922.	27.0	298
312	A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerging Microbes and Infections, 2015, 4, 1-5.	6.5	74
313	Insights into the function of tegument proteins from the varicella zoster virus. Science China Life Sciences, 2015, 58, 739-749.	4.9	7
314	Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine, 2015, 33, 3940-3946.	3.8	21
315	Modeling the long-term antibody response of a hepatitis E vaccine. Vaccine, 2015, 33, 4124-4129.	3.8	24
316	Construction and characterization of an infectious cDNA clone of Echovirus 25. Virus Research, 2015, 205, 41-44.	2.2	9
317	Rapid Fluorescent Lateral-Flow Immunoassay for Hepatitis B Virus Genotyping. Analytical Chemistry, 2015, 87, 5173-5180.	6.5	59
318	Lessons from hepatitis E vaccine design. Current Opinion in Virology, 2015, 11, 130-136.	5.4	27
319	Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate. Vaccine, 2015, 33, 2606-2613.	3.8	24
320	A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine. Applied Microbiology and Biotechnology, 2015, 99, 4845-4853.	3.6	14
321	Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Research, 2015, 25, 604-620.	12.0	69
322	Construction and characterization of an infectious clone of coxsackievirus A6 that showed high virulence in neonatal mice. Virus Research, 2015, 210, 165-168.	2.2	21
323	Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6129-38.	7.1	118
324	Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment. Human Vaccines and Immunotherapeutics, 2015, 11, 1129-1139.	3.3	21

#	Article	IF	CITATIONS
325	A Comprehensive Study of Neutralizing Antigenic Sites on the Hepatitis E Virus (HEV) Capsid by Constructing, Clustering, and Characterizing a Tool Box. Journal of Biological Chemistry, 2015, 290, 19910-19922.	3.4	45
326	<i>In vitro</i> affinity maturation and characterization of anti-P24 antibody for HIV diagnostic assay. Journal of Biochemistry, 2015, 158, mvv070.	1.7	2
327	Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody. Antiviral Research, 2015, 122, 101-111.	4.1	8
328	A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages. Vaccine, 2015, 33, 374-381.	3.8	19
329	Scanning-fluorescence Reader Based on Embedded System. Telkomnika (Telecommunication Computing) Tj ETQ	q1 _{0.8} 0.784	13]4 rgBT /C
330	Epidemiology of Zoonotic Hepatitis E: A Community-Based Surveillance Study in a Rural Population in China. PLoS ONE, 2014, 9, e87154.	2.5	48
331	A One-Step, Triplex, Real-Time RT-PCR Assay for the Simultaneous Detection of Enterovirus 71, Coxsackie A16 and Pan-Enterovirus in a Single Tube. PLoS ONE, 2014, 9, e102724.	2.5	22
332	In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody against Lethal Enterovirus 71 Infection in a Mouse Model. PLoS ONE, 2014, 9, e109391.	2.5	14
333	Protection against Lethal Enterovirus 71 Challenge in Mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop. Theranostics, 2014, 4, 498-513.	10.0	52
334	Safety of an <i>Escherichia coli</i> -expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 469-475.	3.3	29
335	Investigation of a special neutralizing epitope of HEV E2s. Protein and Cell, 2014, 5, 950-953.	11.0	2
336	Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Human Vaccines and Immunotherapeutics, 2014, 10, 740-746.	3.3	28
337	Hepatitis E Vaccine to Prevent Morbidity and Mortality During Epidemics. Open Forum Infectious Diseases, 2014, 1, ofu098.	0.9	17
338	Comparison of Three Luminescent Immunoassays for Hepatitis B Virus Surface Antigen Quantification during the Natural History of Chronic Hepatitis B Virus Infection. Vaccine Journal, 2014, 21, 1521-1527.	3.1	4
339	Identification of a highly conserved and surface exposed Bâ€eell epitope on the nucleoprotein of influenza A virus. Journal of Medical Virology, 2014, 86, 995-1002.	5.0	14
340	Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen. Human Vaccines and Immunotherapeutics, 2014, 10, 1013-1023.	3.3	9
341	Rationally respond to post-vaccination adverse events. Science China Life Sciences, 2014, 57, 557-560.	4.9	O
342	Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine, 2014, 32, 2859-2865.	3.8	36

#	Article	IF	Citations
343	HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cellular and Molecular Immunology, 2014, 11, 175-183.	10.5	90
344	Development of an enzyme-linked immunospot assay for determination of rotavirus infectivity. Journal of Virological Methods, 2014, 209, 7-14.	2.1	15
345	An important amino acid in nucleoprotein contributes to influenza A virus replication by interacting with polymerase PB2. Virology, 2014, 464-465, 11-20.	2.4	8
346	Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. Vaccine, 2014, 32, 1921-1931.	3.8	34
347	Development of an Enzyme-Linked Immunosorbent Spot Assay To Measure Serum-Neutralizing Antibodies against Coxsackievirus B3. Vaccine Journal, 2014, 21, 312-320.	3.1	15
348	Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay. Journal of Virological Methods, 2014, 200, 10-14.	2.1	9
349	Sumoylation of Influenza A Virus Nucleoprotein Is Essential for Intracellular Trafficking and Virus Growth. Journal of Virology, 2014, 88, 9379-9390.	3.4	53
350	Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin $\hat{A}^{\text{@}}$. Vaccine, 2014, 32, 4039-4050.	3.8	71
351	A Convenient Nucleic Acid Test on the Basis of the Capillary Convective PCR for the On-Site Detection of Enterovirus 71. Journal of Molecular Diagnostics, 2014, 16, 452-458.	2.8	19
352	Open Reading Frame 3 of Genotype 1 Hepatitis E Virus Inhibits Nuclear Factor-κappa B Signaling Induced by Tumor Necrosis Factor-α in Human A549 Lung Epithelial Cells. PLoS ONE, 2014, 9, e100787.	2.5	30
353	Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B. Medicine (United States), 2014, 93, e322.	1.0	58
354	An assessment of hepatitis <scp>E</scp> virus (HEV) in <scp>US</scp> blood donors and recipients: no detectable <scp>HEV RNA</scp> in 1939 donors tested and no evidence for <scp>HEV</scp> transmission to 362 prospectively followed recipients. Transfusion, 2013, 53, 2505-2511.	1.6	95
355	Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science, 2013, 340, 1113-1117.	12.6	656
356	Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends in Biotechnology, 2013, 31, 654-663.	9.3	166
357	Specific primer amplification of the VP1 region directed by 5′ UTR sequence analysis: Enterovirus testing and identification in clinical samples from hand-foot-and-mouth disease patients. Journal of Virological Methods, 2013, 193, 463-469.	2.1	42
358	A one-step dipstick assay for the on-site detection of nucleic acid. Clinical Biochemistry, 2013, 46, 1852-1856.	1.9	13
359	Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. Science, 2013, 342, 592-598.	12.6	797
360	Hepatitis E virus capsid protein assembles in $4 < i > M < /i >$ urea in the presence of salts. Protein Science, 2013, 22, 314-326.	7.6	17

#	Article	IF	Citations
361	Maximizing Antibody Production in Suspension-Cultured Mammalian Cells by the Customized Transient Gene Expression Method. Bioscience, Biotechnology and Biochemistry, 2013, 77, 1207-1213.	1.3	16
362	Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: Current genotyping of EV71 does not reflect their antigenicity. Vaccine, 2013, 31, 425-430.	3.8	41
363	Development of a novel baculovirus titration method using the Enzyme-linked immunosorbent spot (ELISPOT) assay. Journal of Virological Methods, 2013, 188, 114-120.	2.1	11
364	Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. Journal of Gastroenterology, 2013, 48, 159-168.	5.1	34
365	Specific interaction between hnRNP H and HPV16 L1 proteins: Implications for late gene auto-regulation enabling rapid viral capsid protein production. Biochemical and Biophysical Research Communications, 2013, 430, 1047-1053.	2.1	8
366	Development of the Hepatitis E Vaccine: From Bench to Field. Seminars in Liver Disease, 2013, 33, 079-088.	3.6	32
367	Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults. Human Vaccines and Immunotherapeutics, 2013, 9, 2474-2479.	3.3	24
368	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut, 2013, 62, 182.2-184.	12.1	67
369	Acetylcholinesteraseâ€Catalyzed Hydrolysis Allows Ultrasensitive Detection of Pathogens with the Naked Eye. Angewandte Chemie - International Edition, 2013, 52, 14065-14069.	13.8	123
370	Structure of a Novel Shoulder-to-Shoulder p24 Dimer in Complex with the Broad-Spectrum Antibody A10F9 and Its Implication in Capsid Assembly. PLoS ONE, 2013, 8, e61314.	2.5	3
371	Seroprevalence of Hepatitis E Virus Infection among Swine Farmers and the General Population in Rural Taiwan. PLoS ONE, 2013, 8, e67180.	2.5	21
372	The Cross-Neutralizing Activity of Enterovirus 71 Subgenotype C4 Vaccines in Healthy Chinese Infants and Children. PLoS ONE, 2013, 8, e79599.	2.5	62
373	ORF7 of Varicella-Zoster Virus Is a Neurotropic Factor. Journal of Virology, 2012, 86, 8614-8624.	3.4	44
374	Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18471-18476.	7.1	75
375	Hepatitis E vaccine development. Human Vaccines and Immunotherapeutics, 2012, 8, 823-827.	3.3	85
376	Hepatitis E. Lancet, The, 2012, 379, 2477-2488.	13.7	805
377	Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. Journal of Hepatology, 2012, 57, 720-729.	3.7	158
378	Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. Virology Journal, 2012, 9, 118.	3.4	21

#	Article	IF	CITATIONS
379	Estrogen Receptor α Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4α. Gastroenterology, 2012, 142, 989-998.e4.	1.3	105
380	A highly specific ELISA for diagnosis of 2009 influenza A (H1N1) virus infections. Journal of the Formosan Medical Association, 2012, 111, 693-697.	1.7	11
381	Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. Reviews in Medical Virology, 2012, 22, 339-349.	8.3	58
382	Safety of the hepatitis E vaccine for pregnant women: A preliminary analysis. Hepatology, 2012, 55, 2038-2038.	7.3	70
383	The enhancement of RNAi against HIV in vitro and in vivo using H-2Kk protein as a sorting method. Journal of Virological Methods, 2012, 182, 9-17.	2.1	8
384	Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease. Virology Journal, 2012, 9, 12.	3.4	17
385	Au@organosilica multifunctional nanoparticles for the multimodal imaging. Chemical Science, 2011, 2, 1463.	7.4	73
386	Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10266-10271.	7.1	109
387	Evaluation of a new rapid influenza A diagnostic test for detection of pandemic (H1N1) 2009 and seasonal influenza A virus. Journal of Clinical Virology, 2011, 50, 153-155.	3.1	8
388	Structural and biophysical characterization of Mycobacterium tuberculosis dodecin Rv1498A. Journal of Structural Biology, 2011, 175, 31-38.	2.8	13
389	Development of an IgM-capture ELISA for Coxsackievirus A16 infection. Journal of Virological Methods, 2011, 171, 107-110.	2.1	18
390	Homology model and potential virus-capsid binding site of a putative HEV receptor Grp78. Journal of Molecular Modeling, 2011, 17, 987-995.	1.8	40
391	Clinical characteristics and risk factors of sporadic Hepatitis E in central China. Virology Journal, 2011, 8, 152.	3.4	35
392	Investigating an outbreak of acute viral hepatitis caused by hepatitis E virus variants in Karachi, South Pakistan. Journal of Medical Virology, 2011, 83, 622-629.	5.0	24
393	Properties and Therapeutic Efficacy of Broadly Reactive Chimeric and Humanized H5-Specific Monoclonal Antibodies against H5N1 Influenza Viruses. Antimicrobial Agents and Chemotherapy, 2011, 55, 1349-1357.	3.2	11
394	Mimotope ELISA for Detection of Broad Spectrum Antibody against Avian H5N1 Influenza Virus. PLoS ONE, 2011, 6, e24144.	2.5	10
395	Antibody reactivity of conformational peptide mimics of a conserved H5N1 neutralization site in different fusion proteins. Archives of Virology, 2010, 155, 19-26.	2.1	1
396	Variability of the S gene of hepatitis B virus in southeastern China. Archives of Virology, 2010, 155, 1951-1957.	2.1	7

#	Article	IF	Citations
397	A rapid test for the detection of influenza A virus including pandemic influenza A/H1N1 2009. Journal of Virological Methods, 2010, 167, 100-102.	2.1	19
398	A novel immunoassay for PreS1 and/or core-related antigens for detection of HBsAg variants. Journal of Virological Methods, 2010, 168, 108-113.	2.1	17
399	RNA Interference inhibits Hepatitis B Virus of different genotypes in Vitro and in Vivo. BMC Microbiology, 2010, 10, 214.	3.3	23
400	Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. Antiviral Research, 2010, 87, 81-84.	4.1	8
401	Molecular and Phylogenetic Analyses Suggest an Additional Hepatitis B Virus Genotype "l― PLoS ONE, 2010, 5, e9297.	2.5	123
402	A Comparative Proteomic Analysis Reveals a New Bi-Lobe Protein Required for Bi-Lobe Duplication and Cell Division in Trypanosoma brucei. PLoS ONE, 2010, 5, e9660.	2.5	58
403	Performance of Detecting IgM Antibodies against Enterovirus 71 for Early Diagnosis. PLoS ONE, 2010, 5, e11388.	2.5	44
404	Novel Double-Antigen Sandwich Immunoassay for Human Hepatitis B Core Antibody. Vaccine Journal, 2010, 17, 464-469.	3.1	77
405	Prevalence of Hepatitis E Virus in Chinese Blood Donors. Journal of Clinical Microbiology, 2010, 48, 317-318.	3.9	96
406	Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors in Southeast China. Journal of Clinical Microbiology, 2010, 48, 357-362.	3.9	64
407	Genome-Wide Mutagenesis Reveals That ORF7 Is a Novel VZV Skin-Tropic Factor. PLoS Pathogens, 2010, 6, e1000971.	4.7	105
408	Metal Core Organosilica Shell Multifunctional Nanoparticles for Multimodal Cell Imaging. , 2010, , .		0
409	Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet, The, 2010, 376, 895-902.	13.7	658
410	Role of heat-shock protein 90 in hepatitis E virus capsid trafficking. Journal of General Virology, 2010, 91, 1728-1736.	2.9	64
411	Profile of Acute Infectious Markers in Sporadic Hepatitis E. PLoS ONE, 2010, 5, e13560.	2.5	114
412	Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host Interaction. PLoS Pathogens, 2009, 5, e1000537.	4.7	123
413	Broad Cross-Protection against H5N1 Avian Influenza Virus Infection by Means of Monoclonal Antibodies that Map to Conserved Viral Epitopes. Journal of Infectious Diseases, 2009, 199, 49-58.	4.0	65
414	Expression and purification of soluble HIV-1 envelope glycoprotein gp160 mutant from Saccharomyces cerevisiae. Journal of Bioscience and Bioengineering, 2009, 108, 5-10.	2.2	4

#	Article	IF	Citations
415	Clinical Significance of Anti-HEV IgA in Diagnosis of Acute Genotype 4 Hepatitis E Virus Infection Negative for Anti-HEV IgM. Digestive Diseases and Sciences, 2009, 54, 2512-8.	2.3	36
416	Poly(styrene-alt-maleic anhydride) derivatives as potent anti-HIV microbicide candidates. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1903-1907.	2.2	27
417	Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine, 2009, 27, 1869-1874.	3.8	113
418	Tetracysteine as a Reporter for Gene Therapy. Biomedical and Environmental Sciences, 2009, 22, 496-501.	0.2	2
419	Peptide mimics of a conserved H5N1 avian influenza virus neutralization site. Biochemical Journal, 2009, 419, 133-139.	3.7	6
420	Prediction of a common neutralizing epitope of H5N1 avian influenza virus by in silico molecular docking. Science Bulletin, 2008, 53, 868-877.	9.0	2
421	Evaluation of a rapid test for detection of H5N1 avian influenza virus. Journal of Virological Methods, 2008, 154, 213-215.	2.1	21
422	Antigenic Profile of Avian H5N1 Viruses in Asia from 2002 to 2007. Journal of Virology, 2008, 82, 1798-1807.	3.4	100
423	Putative receptor-binding sites of hepatitis E virus. Journal of General Virology, 2008, 89, 245-249.	2.9	75
424	Specific Cellular Immune Response in Hepatitis E Patients. Intervirology, 2008, 51, 322-327.	2.8	23
425	Immune Response Induced by a Different Combined Immunization of HBsAg Vaccine. Intervirology, 2007, 50, 336-340.	2.8	0
426	Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity. Molecular Immunology, 2007, 44, 3261-3266.	2.2	22
427	Construction and characterization of the chimeric antibody 8C11 to the hepatitis E virus. FEMS Immunology and Medical Microbiology, 2007, 51, 18-25.	2.7	6
428	Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1691-1701.	4.9	20
429	Seroprevalence of Hepatitis E Virus Infection, Rural Southern People's Republic of China. Emerging Infectious Diseases, 2006, 12, 1682-1688.	4.3	117
430	Variants of Green Fluorescent Protein GFPxm. Marine Biotechnology, 2006, 8, 560-566.	2.4	11
431	Swine as a Principal Reservoir of Hepatitis E Virus That Infects Humans in Eastern China. Journal of Infectious Diseases, 2006, 193, 1643-1649.	4.0	116
432	Significance of serum IgA in patients with acute hepatitis E virus infection. World Journal of Gastroenterology, 2006, 12, 3919.	3.3	32

#	Article	IF	Citations
433	Variants of Green Fluorescent Protein GFPxm. Marine Biotechnology, 2006, 8, 560.	2.4	1
434	Mutational Analysis of Essential Interactions Involved in the Assembly of Hepatitis E Virus Capsid. Journal of Biological Chemistry, 2005, 280, 3400-3406.	3.4	78
435	Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus. World Journal of Gastroenterology, 2005, 11, 492.	3. 3	17
436	Hydrophobicity of reactive site loop of SCCA1 affects its binding to hepatitis B virus. World Journal of Gastroenterology, 2005, 11, 2864.	3.3	0
437	A rapid and efficient method to express target genes in mammalian cells by baculovirus. World Journal of Gastroenterology, 2004, 10, 1612.	3.3	47
438	Selection of a peptide mimicking neutralization epitope of hepatitis E virus with phage peptide display technology. World Journal of Gastroenterology, 2004, 10, 1583.	3.3	15
439	High-yield expression of recombinant SARS coronavirus nucleocapsid protein in methylotrophic yeastPichia pastoris. World Journal of Gastroenterology, 2004, 10, 3602.	3.3	12
440	Expression of ORF2 partial gene of hepatitis E virus in tomatoes and immunoactivity of expression products. World Journal of Gastroenterology, 2003, 9, 2211.	3.3	59
441	Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. World Journal of Gastroenterology, 2003, 9, 996.	3.3	68
442	Bioluminescence of Aequorea macrodactyla, a Common Jellyfish Species in the East China Sea. Marine Biotechnology, 2002, 4, 155-162.	2.4	41
443	Prevalence, isolation, and partial sequence analysis of hepatitis E virus from domestic animals in China. Journal of Medical Virology, 2002, 67, 516-521.	5.0	159
444	Appraisal of green fluorescent protein as a model substrate for seryl-histidine dipeptide cleaving agent. International Journal of Peptide Research and Therapeutics, 2002, 9, 5-10.	0.1	1
445	Title is missing!. International Journal of Peptide Research and Therapeutics, 2002, 9, 5-10.	0.1	5
446	Differential Expression of a Stress-modulating Gene, BRE, in the Adrenal Gland, in Adrenal Neoplasia, and in Abnormal Adrenal Tissues. Journal of Histochemistry and Cytochemistry, 2001, 49, 491-499.	2.5	22
447	Nanospheres from coordination polymers of Ag+ with a highly hydrophilic thiol ligand in situ formed from dynamic covalent binding and a hydrophobic thiol. New Journal of Chemistry, 0, , .	2.8	2